UCB’s monoclonal antibody Bimzelx (bimekizumab) reduced symptoms of psoriatic arthritis in adult patients by 50 percent, according to topline results from a late-stage study.

The phase 3 trial data also showed that Bimzelx significantly improved physical function and skin clearance vs. placebo following 16 weeks of treatment. The 400-person study evaluated the drug only in those who did not adequately respond to or were intolerant of anti-tumor necrosis-factor alpha therapies.

UCB plans to seek approval of Bimzelx as a psoriatic arthritis treatment in both the U.S. and EU during the third quarter of this year.